Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Leerink Affirms Ironwood Pharma (IRWD) at 'Market Perform'; No Catalyst Seen in Next 12 - 18 Months
November 4, 2015 9:09 AM ESTLeerink affirms Ironwood Pharma (Nasdaq: IRWD) with a Market Perform rating and $12 price target following Q3 results issued Tuesday night.
Analyst Jason Gerberry commented, IRWD reported 3Q Linzess sales of ~$117 million coming in modestly below our est. of ~$121 million. The miss was modest, and we dont... More
Ironwood Pharma (IRWD) Misses Q3 EPS by 5c
November 3, 2015 4:23 PM ESTIronwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.25), $0.05 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $39.6 million versus the consensus estimate of $41.76 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More